Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) Director George M. Jenkins bought 4,000 shares of Palvella Therapeutics stock in a transaction dated Wednesday, December 18th. The shares were bought at an average cost of $12.93 per share, with a total value of $51,720.00. Following the completion of the acquisition, the director now owns 180,671 shares of the company’s stock, valued at $2,336,076.03. The trade was a 2.26 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Palvella Therapeutics Price Performance
Shares of NASDAQ:PVLA opened at $12.05 on Friday. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $22.32. The company has a market capitalization of $15.91 million, a P/E ratio of -1.00 and a beta of 0.61.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday. They set an “overweight” rating for the company.
Featured Articles
- Five stocks we like better than Palvella Therapeutics
- What is the S&P/TSX Index?
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- Business Services Stocks Investing
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- Investing in the High PE Growth Stocks
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
